Sepiapterin Patent Expiration
Sepiapterin was first introduced by Ptc Therapeutics Inc
Sepiapterin Patents
Given below is the list of patents protecting Sepiapterin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sephience | US12257252 | Compositions And Methods For Increasing Tetrahydrobiopterin Plasma Exposure | Mar 06, 2042 | Ptc Therap |
| Sephience | US11752154 | Pharmaceutical Compositions Comprising Sepiapterin And Uses Thereof | Sep 04, 2038 | Ptc Therap |
| Sephience | US12213982 | Pharmaceutical Compositions Comprising Sepiapterin And Uses Thereof | Sep 04, 2038 | Ptc Therap |
| Sephience | US11072614 | Polymorphs Of Sepiapterin And Salts Thereof | Apr 16, 2038 | Ptc Therap |
Sepiapterin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Sepiapterin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Sepiapterin in Participants With Phenylketonuria (PKU) | PTC Therapeutics | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |